Amneal Pharmaceuticals LLC (NASDAQ: IPXL), a privately-held generic pharmaceutical manufacturing company headquartered in New Jersey, has agreed to a definitive business combination with California-based speciality pharmaceutical company, Impax Laboratories Inc., in an all-stock transaction, it was reported on Tuesday.
According to the deal, Amneal Holdings members will own approximately 75% and Impax shareholders will own approximately 25% of the new company's pro forma shares on an as converted basis.
The combined company is to be named Amneal Pharmaceuticals Inc., and will have a generics business that will rank as the fifth largest in the United States by gross revenue and a growing, high-margin specialty franchise. The companies said that the transaction is expected to enhance the combined organisation's competitive position and allow for continued success in an evolving generics market.
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling
Sandoz's Tyruko (natalizumab-sztn) gains FDA approval as first biosimilar for relapsing MS
Nephron Pharmaceutical names new chief procurement officer
Lupin Pharmaceuticals launches Tiotropium Bromide Inhalation Powder, 18mcg/capsule in US